Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ixovex-1 · 1 trial · 2 indications
Percentage of subjects with DLTs during the DLT period \[Day 1 to Day 28\]. Percentage of subjects with SAEs, overall and by maximum severity \[Day 1 to 30 days after last dose\]. Percentage of subjects with TEAEs, overall and by maximum severity \[Day 1 to 30 days after last dose\].
Percentage of subjects with TEAEs, overall and by maximum severity \[Day 1 to 30 days after last dose\].
| Arm | Type | Description |
|---|---|---|
| Phase Ia | EXPERIMENTAL | In Phase Ia, subjects will receive Ixovex-1 intratumourally. |
| Phase Ib | EXPERIMENTAL | In Phase Ib, subjects will receive combination therapy with Ixovex-1 intratumourally and Pembrolizumab at the standard dose. |
| Phase II | EXPERIMENTAL | In Phase II, subjects will receive combination therapy with Ixovex-1 intratumourally and Pembrolizumab at the standard dose. |
| Name | Type | Description |
|---|---|---|
| Ixovex-1 | BIOLOGICAL | Ixovex-1 is a novel oncolytic human adenovirus serotype 5. |
| Pembrolizumab | BIOLOGICAL | Humanised antibody |
Inclusion Criteria: 1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Have signed an informed consent indicating that the subject is aware of the neoplastic nature of their d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Ixovex-1 is an investigational monoclonal antibody being developed for the treatment of solid tumors, including head and neck cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Ixovex-1 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied in a Phase 1 trial for solid tumors, including head and neck cancer, with biomarker-selected patients.
Ixovex-1 is being developed by IQVIA Holdings, Inc., a company traded on the New York Stock Exchange under the ticker symbol IQV. The drug is currently in Phase 1 clinical development for solid tumors.
Ixovex-1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants.
Ixovex-1 is being studied in a Phase 1 clinical trial with the identifier NCT06549946, titled 'Ixovex-1 Single Agent and Combination Therapy.' The trial is recruiting participants in the United Kingdom and is expected to enroll 18 patients with solid tumors, including head and neck cancer.
No alternative names for Ixovex-1 have been disclosed. The drug is known only by its development name, Ixovex-1, and is being studied under the clinical trial identifier NCT06549946.